PRIMARY MYELOFIBROSIS
DOI:
https://doi.org/10.24293/ijcpml.v25i1.1518Keywords:
Primary myelofibrosis, chronic myeloid leukemia, hypoplastic marrowAbstract
A 55-year-old male was admitted to hospital with chief complaint of abdominal distention since one year before admission, and it became more prominent than before. The physical examination showed splenomegaly with schuffner line S5, and it was confirmed with ultrasonography. The routine blood test showed a hemoglobin level of 9.2 g/L, leukocyte count of 14.690/µL and thrombocyte count of 115 x 103/µL. From the peripheral blood smear results, the suspected diagnosis of chronic myeloid leukemia with differential diagnosis of a leukemoid reaction was made. However, bone marrow aspiration revealed hypoplastic marrow of primary myelofibrosis. The patients with primary myelofibrosis need early diagnosis and treatment to manage the symptoms of splenomegaly, stop fibrosis process and extramedullary hematopoiesis. Early treatment, in this case, can decrease poor prognosis and mortality rate.
Downloads
References
Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, et al. Thrombosis in primary myelofibrosis: Incidence and risk factors. The United States of America. The American Society of Hematology, 2010; 115(4): 778-782.
Tefferi A. Primary myelofibrosis: 2013 Update on diagnosis, risk-stratification, and management. Annual clinical updates in hematological malignancies: A continuing medical education series. The United States of America. Wiley Periodicals Inc. American Journal of Hematology, 2013; 141-150.
Mascarenhas JO, Orazi A, Bhalla KN, Champlin RE, Harrison C, et al. Advance in myelofibrosis: A clinical case approach. The United States of America. Ferrata Storti Foundation, 2013; 98(10): 1499-1509.
Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, et al. New prognostic scoring system for primary myelofibrosis based on a study of International Working Group for myelofibrosis research and treatment. The American Society of Hematology. The United States of America, 2009; 113(3): 2895-2901.
Clark DA, Williams WL. Myelofibrosis. Myeloproliferative disorders. In: Hematologic Malignancies. Wintrobe's clinical hematology. 11th Ed., United States of America. Lippincott Williams & Wilkins Publisher, 2003; 376.
Vassiliou G, Green AR. Idiopathic myelofibrosis. In: Myeloproliferative disorders. Chapter 46. Postgraduate hematology. 5th Ed., Australia, Blackwell Publishing Ltd, 2005; 771 – 775.
Mesa RA, Tefferi A. Approach to chronic idiopathic myelofibrosis (with extramedullary hematopoiesis). In: Clinical malignant hematology. The United States of America. The McGraw Hill, 2007; 475 – 480.
Komrokji RS, Verstovsek S, Padron E. Advances in the management of myelofibrosis. The United States of America. Department of Malignant Hematology, 2012; 19(4): 4-15.
Callum J. New diagnostic criteria. Primary myelofibrosis. 2008 January. Available from URL: http://sunnybrook.ca/uploads/Primary_Myelofibrosis.pdf.Accessed August 27, 2014.
Mehta J. Primary myelofibrosis. Myeloproliferative Neoplasm Research Foundation. 2014. Available from URL: http://www.mpnresearchfoundation.org/Primary-Myelofibrosis. Accessed August 27, 2014.
Spivak JL. Chronic idiopathic myelofibrosis. In: Harrison's hematology and oncology. The United States of America. McGraw Hill Companies Inc. 2010; 158 – 195.
Provan D. Idiopathic myelofibrosis. Oxford handbook of clinical hematology. 2nd Ed., New York, Oxford University Press, 2004; 256 – 258.
Nwannadi IA. The Epidemiology of hematological malignancies at the University of Benin Teaching Hospital: A ten-year retrospective study. Nigeria. The Internet Journal of Epidemiology, 2010; 9(2): 1 – 6.
Loffler H, Helmut, Rastetter, Johann, Haferlach, et al. Chronic myeloproliferative disorders. Atlas of clinical hematology. 6th Ed., Germany, Springer, 2005; 27.
Cruse JM, Lewis RE. Molecules, cells, and tissue of the immune response. In: Atlas of immunology. 2nd Ed., United States of America, CRC Press, 2004; 76.
Hoffman R, Rondelli D. Biology and treatment of primary myelofibrosis. Myeloproliferative disorders. The United States of America, ASH Education Book, 2007; 346-354.
Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Journal of Clinical Oncology. American Society of Clinical Oncology, 2009; 27: 5587-5593.
Tefferi A. Myelofibrosis facts. Leukemia and lymphoma society. The United States of America. 2012 April. Available from URL: http.LLS.org. Accessed August 27, 2014.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 1970 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
